1. Use of an antibody to IL-1α to reduce the likelihood of serious adverse clinical phenomena occurring in a human subject who received surgical treatment of blood vessel stenosis or its waiting polucheniya.2. Use according to Claim. 1, wherein the antibody to IL-1α is a monoclonal antitelo.3. Use according to claim. 2, wherein the monoclonal antibody is a IgG1.4. Use according to claim. 2, wherein the monoclonal antibody comprises a complementarity determining region of MABp1.5. Use according to claim. 2, wherein the monoclonal antibody is a MABp1.6. Use of an antibody to IL-1α to reduce the likelihood of restenosis occurring in a human subject who received surgical treatment of blood vessel stenosis or its waiting polucheniya.7. Use according to claim. 6, wherein the antibody to IL-1α is a monoclonal antitelo.8. Use according to claim. 7 wherein the monoclonal antibody is a IgG1.9. Use according to claim. 7 wherein the monoclonal antibody comprises a complementarity determining region of MABp1.10. Use according to claim. 7 wherein the monoclonal antibody is a MABp1.11. A method of reducing likelihood of serious adverse clinical phenomena occurring in a human subject who received surgical treatment of stenosis of the blood vessel or awaiting receipt, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an antibody to IL-1α, effective to reduce the likelihood of serious adverse clinical phenomena occurring at subekta.12. A method of reducing the likelihood of1. Применение антитела к IL-1α для снижения вероятности возникновения серьезного нежелательного клинического явления, имеющего место у субъекта-человека, получившего хирургическое лечение стеноза кровеносного сосуда или ожидающего его получения.2. Применение по п. 1, где антитело к IL-1α представляет собой моноклональное антитело.3. Применение по п. 2, где моноклональное антитело представляет собой IgG1.4. Пр
